Cellebrite DI (CLBT)
NASDAQ:CLBT
Want to see CLBT full AI Analyst Report?
Top Page
Cellebrite DI
(NASDAQ:CLBT)
Select Model
Select Model
Rating:69Neutral
Price Target:
$15.00
▲(13.81% Upside)
Action:DowngradedDate:04/11/26
The score is driven primarily by strong fundamentals—especially robust free cash flow and a low-leverage balance sheet—supported by positive 2026 guidance and outlook from the earnings call. Offsetting these strengths are weak technicals (clear downtrend with oversold momentum) and a relatively expensive valuation (high P/E), which raise near-term risk and reduce upside certainty.
Positive Factors
Strong free cash flow generation
Sustained, high free cash flow (~$160M TTM) and ~91% free cash flow conversion provide durable internal funding for R&D, product development, tuck‑ins and working capital. This cash robustness reduces reliance on external financing and supports strategic investments over the next 2–6 months and beyond.
Negative Factors
FedRAMP / federal timing dependency
Dependence on FedRAMP/ATO approvals creates structural timing risk for federal cloud uptake and Guardian penetration. Long certification cycles and earlier 2025 federal disruptions produced meaningful ARR headwinds, making a portion of the company's growth cadence contingent on external regulatory timelines.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow generation
Sustained, high free cash flow (~$160M TTM) and ~91% free cash flow conversion provide durable internal funding for R&D, product development, tuck‑ins and working capital. This cash robustness reduces reliance on external financing and supports strategic investments over the next 2–6 months and beyond.
Read all positive factors
Cellebrite DI (CLBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.40B
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)56.3
Beta (1Y)0.76
Revenue Growth18.56%
EPS GrowthN/A
CountryUS
Employees1,167
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)0.32
Shares Outstanding249,439,820
10 Day Avg. Volume1,868,341
30 Day Avg. Volume1,632,704
Financial Highlights & Ratios
PEG Ratio-0.47
Price to Book (P/B)9.41
Price to Sales (P/S)9.58
P/FCF Ratio29.25
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.94
Enterprise Value/Gross Profit8.24
Enterprise Value/Ebitda39.46
Forecast
1Y Price Target
$20.67Price Target Upside56.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.37
Revenue Forecast (FY)$568.47M
Cellebrite DI Business Overview & Revenue Model
Company Description
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and...
How the Company Makes Money
Cellebrite makes money primarily by selling subscriptions and licenses to its digital intelligence software and platforms, along with associated maintenance/support and professional services. Key revenue streams generally include: (1) Software/pla...
Cellebrite DI Key Performance Indicators (KPIs)
Cellebrite DI Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Positive
The call conveys a predominantly positive outlook: the company reported healthy ARR, revenue, profitability and free cash flow expansion in 2025, demonstrated strong SaaS/cloud and Guardian growth, achieved above-target Insights conversion, completed the Keryllium acquisition and announced a strategic drone-forensics tuck-in. Management acknowledged transitory headwinds — U.S. federal disruptions earlier in 2025, FedRAMP timing, FX impacts, and near-term acquisition-related margin pressure — but presented a clear path to ARR reacceleration and durable FCF margins (>30%) in 2026 with conservative guidance that leaves upside from AI monetization and integration gains.Positive Updates
Strong ARR Growth
ARR grew 21% to $481M in 2025 (includes Keryllium). Excluding Keryllium, ARR grew 17% year-over-year. Sequential ARR increased 6% over Q3 2025. Keryllium contributed $16.1M of ARR following a Dec 1 close.
Negative Updates
U.S. Federal Segment Disruptions (2025 Headwind)
The U.S. federal unit experienced disruptions in 2025 and produced an approximately four-point headwind to ARR growth versus original plan; performance was roughly flat in 2025 but management expects reacceleration in 2026.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong ARR Growth
ARR grew 21% to $481M in 2025 (includes Keryllium). Excluding Keryllium, ARR grew 17% year-over-year. Sequential ARR increased 6% over Q3 2025. Keryllium contributed $16.1M of ARR following a Dec 1 close.
Read all positive updates
Company Guidance
Cellebrite guided to full‑year 2026 ARR of $567–$573 million (18%–19% growth vs. FY25), revenue of $565–$571 million (19%–20% growth), and adjusted EBITDA of $149–$155 million (26%–27% margin); for Q1 it sees ARR of $491–$493 million (20%–21% growth), revenue of $127–$129 million (18%–20%) and adjusted EBITDA of $26–$28 million (21%–22% margin). Management expects free cash flow margins in excess of 30% for 2026, about 60% of adjusted EBITDA dollars in the back half of the year (H2 weighting), a reacceleration versus 2025’s ~17% organic ARR growth (FY25 ARR $481M, +21% incl. Keryllium; Keryllium ARR $16.1M), and emphasized tighter guidance ranges (≈$6M ARR spread vs. prior ~$15M) while targeting a rule‑of‑x in the upper‑40s with an objective of 50+.Cellebrite DI Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
88
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 475.68M | 401.20M | 325.11M | 270.65M | 246.25M |
| Gross Profit | 400.50M | 338.61M | 271.88M | 219.91M | 203.69M |
| EBITDA | 78.35M | 67.51M | -64.80M | 130.10M | 89.47M |
| Net Income | 78.33M | -283.01M | -81.10M | 120.81M | 71.40M |
Balance Sheet | |||||
| Total Assets | 938.85M | 690.57M | 532.88M | 403.29M | 339.78M |
| Cash, Cash Equivalents and Short-Term Investments | 437.05M | 447.22M | 302.92M | 183.62M | 181.56M |
| Total Debt | 22.67M | 10.97M | 14.13M | 15.36M | 0.00 |
| Total Liabilities | 454.53M | 354.55M | 498.67M | 329.43M | 413.13M |
| Stockholders Equity | 484.32M | 336.02M | 34.21M | 73.86M | -73.35M |
Cash Flow | |||||
| Free Cash Flow | 155.73M | 121.56M | 94.14M | 11.49M | 27.94M |
| Operating Cash Flow | 168.96M | 132.17M | 102.06M | 20.58M | 36.05M |
| Investing Cash Flow | -268.25M | -149.47M | -22.54M | -91.23M | 45.23M |
| Financing Cash Flow | 29.64M | 20.65M | 21.77M | 13.97M | -68.40M |
Cellebrite DI Technical Analysis
Positive
13.18
Price Trends
13.81
Negative
15.63
Negative
16.07
Negative
Market Momentum
-0.50
Positive
48.28
Neutral
47.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Positive. The current price of 13.18 is below the 20-day moving average (MA) of 13.31, below the 50-day MA of 13.81, and below the 200-day MA of 16.07, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 48.28 is Neutral, neither overbought nor oversold. The STOCH value of 47.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLBT.
Cellebrite DI Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $1.39B | 16.69 | 5.77% | 4.71% | 7.98% | 993.10% | |
72 Outperform | $2.39B | 346.71 | -3.71% | ― | 10.74% | 74.22% | |
70 Outperform | $1.81B | 12.90 | 23.21% | 0.68% | 10.21% | 26.57% | |
69 Neutral | $3.40B | 56.34 | 18.39% | ― | 18.56% | ― | |
69 Neutral | $1.17B | 43.14 | 5.95% | ― | 9.81% | 228.99% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | $3.15B | -16.86 | -27.04% | ― | 15.27% | -39.93% |
* Technology Sector Average
CLBT
Cellebrite DI
13.64
-6.07
-30.80%
RDWR
Radware
27.23
4.11
17.78%
EVTC
Evertec
29.43
-4.83
-14.10%
VRNS
Varonis Systems
27.41
-16.44
-37.49%
TENB
Tenable Holdings
20.83
-10.43
-33.37%
TUYA
Tuya
2.40
0.17
7.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.